Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/10010
Title: | Use of Meta-Analysis for the Validation of Surrogate Endpoints and Biomarkers in Cancer Trials | Authors: | BUYSE, Marc | Issue Date: | 2009 | Publisher: | LIPPINCOTT WILLIAMS & WILKINS | Source: | CANCER JOURNAL, 15(5). p. 421-425 | Abstract: | This article discusses statistical approaches to the validation of surrogate biomarkers and endpoints. One approach that has been successfully used in oncology consists of estimating associations at two levels: the association between the surrogate and the clinical endpoint, called the individual-level association, and the association between the effects of treatment on the surrogate and the clinical endpoint, called the trial-level association. This approach requires data to be available from multiple randomized trials, such as in a meta-analysis of trials based on individual patient data. The approach is illustrated using randomized trials of first-line treatments for advanced tumors of the colon, breast, ovary, and prostate. Data from several meta-analyses suggest that progression-free survival is an acceptable surrogate in advanced colorectal and ovarian cancer, but not in breast and prostate cancer. | Notes: | [Buyse, Marc] IDDI, B-1340 Louvain, Belgium. [Buyse, Marc] Hasselt Univ, Ctr Stat, I BioStat, Diepenbeek, Belgium. | Keywords: | meta-analysis; surrogate endpoint; biomarker; colorectal cancer; breast cancer; ovarian cancer; prostate cancer | Document URI: | http://hdl.handle.net/1942/10010 | ISSN: | 1528-9117 | e-ISSN: | 1540-336X | ISI #: | 000270918300012 | Category: | A1 | Type: | Journal Contribution | Validations: | ecoom 2010 |
Appears in Collections: | Research publications |
Show full item record
Google ScholarTM
Check
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.